Liver-protective nutritional supplement for people with liver disease from chronic hepatitis C
Evaluation of the Hepatoprotective Effects of a Nutritional Supplement Containing Resveratrol, Quercetin, Taurine, Inulin, and Whey Protein on Biochemical, Molecular, and Clinical Markers in Patients With Liver Disease Secondary to Chronic Hepatitis C Virus Infection (RESQUETI Study).
This project will test whether a daily supplement combining resveratrol, quercetin, taurine, inulin, and whey protein helps people with liver disease from chronic hepatitis C over 12 weeks compared with whey protein alone.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 26 (estimated) |
| Ages | 18 Years to 69 Years |
| Sex | All |
| Sponsor | University of Guadalajara Academic / other |
| Locations | 2 sites (Guadalajara, Jalisco and 1 other locations) |
| Trial ID | NCT07487623 on ClinicalTrials.gov |
What this trial studies
Adults with liver disease secondary to chronic hepatitis C who meet eligibility criteria will take either the combination supplement or an active control (whey protein alone) daily for 12 weeks and attend clinic visits every 4 weeks for laboratory tests and clinical evaluations. The trial compares changes in biochemical and molecular liver biomarkers and clinical assessments between the two groups. Key inclusion criteria include age 18–69 and Child‑Pugh score below 8, while exclusions include recent alcohol use, advanced liver complications, chronic kidney disease, autoimmune disease, cancer, cognitive impairment, or current use of protein supplements or probiotics. The intervention combines several putative hepatoprotective nutrients to determine whether the combination provides additional benefit over protein alone.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18–69 with liver disease due to chronic hepatitis C and a Child‑Pugh score less than 8 who can attend clinic visits in Guadalajara and are not using protein supplements or probiotics.
Not a fit: Patients with recent alcohol use, advanced decompensated liver complications (for example refractory ascites, hepatorenal syndrome, persistent encephalopathy), chronic kidney disease, autoimmune disease, active cancer, or dementia are unlikely to benefit or are excluded.
Why it matters
Potential benefit: If successful, the supplement could improve liver-related biomarkers and clinical status in people with HCV-related liver disease over a 12-week period.
How similar studies have performed: Individual components such as resveratrol and quercetin have shown hepatoprotective effects in preclinical work and small clinical reports, but the specific combination with taurine, inulin, and whey protein in HCV-related liver disease is largely untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients with liver disease secondary to chronic hepatitis C virus infection who attend the outpatient Hepatitis Clinic of the Gastroenterology Department at Hospital Civil Fray Antonio Alcalde. Child-Pugh score \< 8 points. Age 18-69 years. Both sexes. Signed informed consent. \- Exclusion Criteria: * Patients with alcohol consumption within the past 6 months. Patients with a history of acute-on-chronic liver failure (ACLF). Patients with persistent hepatic encephalopathy. Patients unable to perform frailty assessments. Patients with refractory ascites. Patients with a history of hepatorenal syndrome. Patients with a history of hepatopulmonary syndrome. Patients with chronic kidney disease. Patients with autoimmune diseases. Patients with any type of cancer. Patients with dementia or other significant mental illnesses. Use of protein supplements or probiotics.
Where this trial is running
Guadalajara, Jalisco and 1 other locations
- Hospital Civil de Guadalajara Fray Antonio Alcalde — Guadalajara, Jalisco, Mexico (Recruiting)
- Hospital Civil de Guadalajara Fray Antonio Alcalde — Guadalajara, Jalisco, Mexico (Recruiting)
Study contacts
- Study coordinator: Juan Roberto Rodriguez-Echevarria, PhD
- Email: roberto.rodriguez@academico.udg.mx
- Phone: +52 33 18 23 13 10
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.